Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.71 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | GRM5 | P41594 | 1/20 | 0.59 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.59 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.59 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.59 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.59 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.59 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | PYGL | P06737 | 1/20 | 0.58 |
| ▸ | PYGM | P11217 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19246196 | 0.91 | KCNMA1 (0.60) | KCNMA1KCNK3KCNK9MEN1KMT2A | |
| SCHEMBL11779066 | 0.89 | HDAC1 (0.68) | KCNMA1KCNK3KCNK9MEN1KMT2A | |
| SCHEMBL21870103 | 0.89 | POLB (0.68) | KCNMA1KCNK3KCNK9MEN1KMT2A | |
| SCHEMBL27388520 | 0.87 | NPC1 (0.71) | KCNMA1KCNK3KCNK9MEN1KMT2A | |
| SCHEMBL1464661 | 0.87 | MEN1 (0.79) | KCNMA1KCNK3KCNK9MEN1KMT2A | |
| SCHEMBL28345726 | 0.86 | KMT2A (0.69) | KCNMA1KCNK3KCNK9MEN1KMT2A | |
| SCHEMBL1307853 | 0.84 | MEN1 (0.62) | KCNMA1KCNK3KCNK9MEN1KMT2A | |
| SCHEMBL3786882 | 0.84 | KCNK3 (0.87) | KCNK3KCNK9MEN1KMT2ARAB9A | |
| SCHEMBL13802447 | 0.83 | PHGDH (0.72) | KCNMA1L3MBTL1RAB9ANPC1MAPT | |
| SCHEMBL28433330 | 0.83 | RXFP1 (0.57) | KCNMA1KCNK3KCNK9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11825845-B2 | Slippery liquid-infused porous surfaces that release hydrophilic and hydrophobic agents | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-11-28 | — | — | US | disclosed |
| US-20220030869-A1 | Slippery Liquid-Infused Porous Surfaces that Release Hydrophilic and Hydrophobic Agents | NATIONAL SCIENCE FOUNDATION | 2022-02-03 | — | — | US | disclosed |
| US-11046854-B2 | Slippery liquid-infused porous surfaces that prevent microbial surface fouling | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200325347-A1 | SLIPPERY LIQUID-INFUSED POROUS SURFACES THAT PREVENT MICROBIAL SURFACE FOULING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-10-15 | — | — | US | disclosed |
| US-10751495-B2 | Patient interface | KONINKLIJKE PHILIPS N.V. (NL) | 2020-08-25 | — | — | US | disclosed |
| US-10557042-B2 | Slippery liquid-infused porous surfaces that prevent microbial surface fouling | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-10322112-B2 | Compound combinations for attenuation of bacterial virulence | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-18 | — | — | US | disclosed |
| US-20170231962-A1 | Compound Combinations for Attenuation of Bacterial Virulence | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-17 | — | — | US | disclosed |
| US-20160317771-A1 | PATIENT INTERFACE | KONINKLIJKE PHILIPS N.V. | 2016-11-03 | — | — | US | disclosed |
| US-20160317771-A1 | PATIENT INTERFACE | KONINKLIJKE PHILIPS N.V. | 2016-11-03 | — | — | US | disclosed |
| US-20080287546-A1 | Quorum Sensing Modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-20080287546-A1 | Quorum Sensing Modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231962-A1 | Compound Combinations for Attenuation of Bacterial Virulence | PNISR, PGLS, QRFPR | KCNMA1 2890/4885KCNK3 4050/4885KCNK9 3511/4885 |
| US-10557042-B2 | Slippery liquid-infused porous surfaces that prevent microbial surface fouling | CLPP, MSN, Q6ZSR9 | KCNMA1 3029/4885KCNK3 3282/4885KCNK9 2507/4885 |
| US-10322112-B2 | Compound combinations for attenuation of bacterial virulence | PNISR, BLVRB, PGLS | KCNMA1 2692/4885KCNK3 3953/4885KCNK9 3640/4885 |
| US-20200325347-A1 | SLIPPERY LIQUID-INFUSED POROUS SURFACES THAT PREVENT MICROBIAL SURFACE FOULING | CLPP, MSN, Q6ZSR9 | KCNMA1 3029/4885KCNK3 3282/4885KCNK9 2507/4885 |
| US-20220030869-A1 | Slippery Liquid-Infused Porous Surfaces that Release Hydrophilic and Hydrophobic Agents | CLPP, MSN, LIPA | KCNMA1 3897/4885KCNK3 3378/4885KCNK9 3745/4885 |
| US-11046854-B2 | Slippery liquid-infused porous surfaces that prevent microbial surface fouling | CLPP, MSN, Q6ZSR9 | KCNMA1 3029/4885KCNK3 3282/4885KCNK9 2507/4885 |
| US-20080287546-A1 | Quorum Sensing Modulators | BLVRB, Q6ZSR9, PGLS | KCNMA1 3202/4885KCNK3 3592/4885KCNK9 3220/4885 |
| US-11825845-B2 | Slippery liquid-infused porous surfaces that release hydrophilic and hydrophobic agents | CLPP, MSN, LIPA | KCNMA1 3897/4885KCNK3 3378/4885KCNK9 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.